Table 2.
Levodopa Doses by Baseline Dyskinesia Status (Randomized Population)
| No Dyskinesia | Non-Troublesome Dyskinesia Only | Troublesome Dyskinesia | ||||
| Characteristic | CD-LD ER | CD-LD IR | CD-LD ER | CD-LD IR | CD-LD ER | CD-LD IR |
| (N = 91) | (N = 92) | (N = 66) | (N = 65) | (N = 44) | (N = 35) | |
| Mean LD Dose at Baseline (mg)* | 761.5 | 751.4 | 779.0 | 761.2 | 802.3 | 865.0 |
| Mean LD Dose at EOS (mg) | 1611.6 | 788.9 | 1713.9 | 790.0 | 1541.8 | 927.1 |
| Mean Change from Baseline to EOS in LD Dose (mg) | 850.1 | 37.5 | 935.0 | 28.8 | 739.5 | 62.1 |
| Ratio EOS LD Dose to Baseline LD Dose | 2.25 | 1.07 | 2.24 | 1.05 | 2.07 | 1.06 |
| Mean Number of LD administrations at Baseline | 4.8 | 4.6 | 5.1 | 5.1 | 6.0 | 5.4 |
| Mean Number of LD administrations at EOS | 3.5 | 4.7 | 3.7 | 5.2 | 3.7 | 5.5 |
| Mean Change from Baseline to EOS in Number of LD administrations | –1.3 | 0.1 | –1.3 | 0.2 | –2.3 | 0.1 |
| Ratio EOS Number of LD administrations to Baseline Number of LD administrations | 0.75 | 1.03 | 0.77 | 1.04 | 0.69 | 1.02 |
CD-LD ER, carbidopa-levodopa extended release; CD-LD IR, carbidopa-levodopa immediate release; EOS, End of Study; LD, levodopa. *All groups received CD-LD IR at baseline, and assigned formulation (CD-LD ER or CD-LD IR) at EOS.